Evaluering af sikkerheden og effektiviteten af KL003-celleinjektion ved behandling af transfusionsafhængig β-thalassæmi.
This is a non-randomized, open-label, single-dose study. The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells in subjects with transfusion-dependent β-thalassemia.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Subject participation for this study will be 24 months. Subjects who enroll in this study will be asked to participate in a subsequent 13-year follow-up for gene therapy products.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina
- Regenerative Medicine Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female age between 3-35 years
- Diagnosis of transfusion-dependent β-thalassemia and a history of at least 100 mL/kg/year of pRBCs or ≥8 transfusions of pRBCs per year for the prior 2 years
- Documented baseline, or pretransfusion, Hb level≤7 g/dL
- Karnofsky performance status ≥70 for subjects≥16 years of age; Lansky performance status of ≥70 for subjects<16 years of age
- Eligible to undergo auto-HSCT
- Willing and able to follow the research procedures and conditions, with good compliance
- Willing to receive at least the 2 years follow-up and maintain detailed medical records, including transfusion history
- Subject and/or legal guardians voluntarily participated in this clinical trial and signed the informed consent form, and can complete all follow-up in accordance with the protocol requirements
Exclusion Criteria:
-
Subjects positive with the following etiological tests: human immunodeficiency virus(HIV-1-2), human cytomegalovirus (HCMV-DNA), EB virus (EBV-DNA), HBV (HBsAg/HBV-DNA positive), HCV antibody (HCV-Ab), Treponema pallidum antibody (TP-Ab)
-
Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the clinical investigator
-
Contraindication to bone marrow collection
-
Any prior or current malignancy or myeloproliferative or significant immunodeficiency disorder
-
A white blood cell (WBC) count <3×10^9/L, and/or platelet count <100×10^9/L not related to hypersplenism
-
Diagnosis of composite α thalassemia
-
Participants with severe iron overload at the time of screening: severe iron overload of the liver showed by MRI, serum ferritin ≥ 5000 ng/mL, or moderate to severe iron overload of the heart
-
Presence of unusual antibody of red blood cell antigens or tested positive for platelet antibody
-
Meet the criteria for allo-HSCT and with an identified willing donor with a full HLA match
-
Prior receipt of gene therapy or allo-HSCT
-
Immediate family member (i.e. parent or siblings) with a known Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis)
-
Diagnosis of a significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study
-
History of major organ damage including:
- Liver function test suggest AST or ALT levels >3× upper limit of normal (ULN);
- Total serum bilirubin value >2.5×ULN;if combined with Gilbert syndrome, total bilirubin >3×ULN and direct bilirubin value >2.5×ULN;
- History of bridging fibrosis, cirrhosis;
- Left ventricular ejection fraction <45%;
- New York Heart Association (NYHA) class III or IV congestive heart failure;
- Severe arrhythmia requiring medical treatment;
- Uncontrolled hypertension or unstable angina pectoris;
- Myocardial infarction or bypass or stent surgery within 12 months before drug administration;
- Valvular disease with clinical significance;
- Baseline calculated eGFR<60mL/min/1.73m2;
- Pulmonary function: FEV1/FVC<60% and/or diffusion capacity of carbon monoxide (DLco) <60% of prediction;
- Evidence of clinically significant pulmonary hypertension requiring medical intervention.
-
Uncorrectable coagulation dysfunction or history of severe bleeding disorder
-
Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician
-
Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.)
-
Participation in another clinical study with an investigational drug within 30 days of Screening or participating in another clinical study with an investigational drug
-
Inoculated live vaccine within 6 weeks prior to screening
-
Pregnancy or breastfeeding women; Subjects or their sexual partners were unable to take medically recognized effective contraceptive measures during the 27-month study period
-
The subjects or their parents would not comply with the study procedures outlined in the protocol
-
Receipt of hydroxyurea therapy within 3 months before HSCT harvest
-
Patients considered to be ineligible for the study by the investigator for reasons other than the above
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: KL003 cell injection Drug Product
Each recruited subject will accept KL003 Transplantation. |
Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Transplantationsrelateret dødelighed inden for 100 dage og inden for 1 år efter reinfusion af KL003 lægemiddel
Tidsramme: Op til 1 år efter transplantation
|
Op til 1 år efter transplantation
|
|
|
Percentage of participants with successful lentiviral vector transduced CD34+ stem cell engraftment
Tidsramme: Up to 42 days post transplant
|
Successful engraftment was defined as neutrophil count [ANC] ≥0.5×10^9/L for 3 consecutive days |
Up to 42 days post transplant
|
|
Engraftment time of neutrophil
Tidsramme: Up to 42 days post transplant
|
The first day when neutrophils ≥ 0.5×10^9/L for 3 consecutive days |
Up to 42 days post transplant
|
|
Engraftment time of platelet
Tidsramme: Up to 42 days post transplant
|
The first day of platelet count ≥ 20.0×10^9/L for 7 consecutive days after platelet transfusion independence |
Up to 42 days post transplant
|
|
The number, frequency and severity of adverse events (AE) within 1 year after reinfusion of KL003 drug products
Tidsramme: Up to 24 months post transplant
|
Frequency and severity of AEs & SAEs identified according to NCI CTCAE 5.0 |
Up to 24 months post transplant
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Varigheden af transfusionsuafhængighed
Tidsramme: Op til 24 måneder efter transplantation
|
Op til 24 måneder efter transplantation
|
|
|
Ændringer i hyppigheden og volumen af blodtransfusion
Tidsramme: Op til 24 måneder efter transplantation
|
Op til 24 måneder efter transplantation
|
|
|
The proportion of participants who meet the definition of transfusion independence (TI) for at least 6 months
Tidsramme: Up to 24 months post transplant
|
TI is defined as Hb ≥ 90.0 g/L after reinfusion and without disease-related routine blood transfusion for 6 months |
Up to 24 months post transplant
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IIT2023021
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .